https://pubmed.ncbi.nlm.nih.gov/38165333/
This study provides Class I evidence that for patients with gMG, nipocalimab was well-tolerated, and it did not significantly improve MG-ADL at any individual...
safetyefficacynipocalimabpatientsgeneralized
https://www.lupus.org/zh-hans/node/5547/chapter/17
Johnson & Johnson announced positive topline results from its Phase 2 randomized placebo-controlled JASMINE study. The drug therapy, nipocalimab, met its...
positive resultsphasejasminetrialnipocalimab
https://www.pharmaceutical-technology.com/data-insights/nipocalimab-johnson-johnson-net-present-value/
Nipocalimab is a monoclonal antibody commercialized by Johnson & Johnson, with a leading Phase III program in Acquired (Autoimmune) Hemolytic Anemia.
net present valuerisk adjustedcurrentvaluation
https://www.contemporarypediatrics.com/view/jonathan-strober-md-highlights-encouraging-nipocalimab-aahu-data-for-generalized-myasthenia-gravis
Nov 26, 2025 - Contemporary Pediatrics connects pediatricians with peer-reviewed articles, guideline updates, and practice strategies for real-world clinical application.
jonathanstrobermdhighlightsencouraging